Treatment of Giant Cell Arteritis and Takayasu Arteritis—Current and Future

Abstract

Purpose of Review Guidelines for the management of large vessel vasculitides have been recently updated by several scientific societies. We have evaluated the current recommendations for treatment of giant cell arteritis (GCA) and Takayasu arteritis (TA) and addressed potential future therapeutic strategies. Recent Findings While glucocorticoids (GCs) remain the gold standard for induction of remission, many patients relapse and acquire high cumulative GC exposure. Thus, GC-sparing therapies such as methotrexate are recommended for selected patients with GCA and all patients with TA. Recent high-quality evidence shows that tocilizumab is an effective GC-sparing agent in GCA. Non-biologic and biologic immunomodulators also appear to have GC-sparing properties in TA. Summary Tocilizumab is now considered to be part of the standard treatment for GCA, particularly with relapsing disease, but questions on its use such as length of treatment and monitoring of disease activity remain open. High-quality evidence to guide treatment of TA is still lacking.

Multisystemic Sarcoidosis Presenting With Leg Ulcers, Pancytopenia, and Polyserositis Was Successfully Treated With Glucocorticoids: A Case Report and Literature Review

“…But our patient is at high risk of side effects with glucocorticoid therapy because of diabetes history. Conventional and biological immunosuppressive drugs such as methotrexate and tocilizumab have been studied for their glucocorticoid-sparing properties to reduce glucocorticoid exposure and maintain remission ( 4 ). Therefore, we may first consider glucocorticoid-sparing therapy in patients with high-risk factors for glucocorticoid complications.…”

Cardiovascular Risk in Patients With Takayasu Arteritis Directly Correlates With Diastolic Dysfunction and Inflammatory Cell Infiltration in the Vessel Wall: A Clinical, ex vivo and in vitro Analysis

“…To date, the administration of anti-tumor necrosis factor-alpha (TNF-α) agents, such as infliximab, appears to be a valuable and safe alternative to standard therapy ( 4 ). By blocking TNF-α-induced activation of inflammatory signals, infliximab leads to long-term clinical improvement with significant benefits for patients' quality of life ( 8 , 9 ).…”

Performance of leflunomide as a steroid-sparing agent in giant cell arteritis: A single-center, open-label study

“…It is a rheumatologic emergency and as such requires prompt anti-inflammatory treatment to prevent irreversible ischemic complications ( 2 – 4 ). Glucocorticoids remain the cornerstone of treatment due to their rapid onset of action ( 5 ). Unfortunately, almost half of patients relapse during glucocorticoid tapering, and around half after glucocorticoid withdrawal ( 4 , 6 ).…”

“…Unfortunately, almost half of patients relapse during glucocorticoid tapering, and around half after glucocorticoid withdrawal ( 4 , 6 ). Therefore, many patients need prolonged treatment resulting in high cumulative glucocorticoid doses ( 5 ). Therefore, patients are at risk of developing glucocorticoid-related adverse events and complications such as diabetes, arterial hypertension infections, osteoporosis, fractures and steroid myopathy ( 7 ).…”